
==== Front
Animal Model Exp Med
Animal Model Exp Med
10.1002/(ISSN)2576-2095
AME2
Animal Models and Experimental Medicine
2096-5451
2576-2095
John Wiley and Sons Inc. Hoboken

38591343
10.1002/ame2.12407
AME212407
AMEM-2024-0038.R1
Review
Regular Article
Review
Against all odds: The road to success in the development of human immune reconstitution mice
Bin et al.
Bin Yixiao 1 2 3
Ren Jing 1 2 3
Zhang Haowei 4
Zhang Tianjiao 2 3
Liu Peijuan 2 3
Xin Zhiqian 2 3
Yang Haijiao 2 3
Feng Zhuan 2 3
Chen Zhinan 2 3 znchen@fmmu.edu.cn

Zhang Hai https://orcid.org/0000-0002-7999-0208
2 3 hzhang@fmmu.eud.cn

1 School of Basic Medical Sciences Shaanxi University of Chinese Medicine Xianyang China
2 Department of Cell Biology, National Translational Science Center for Molecular Medicine Fourth Military Medical University Xi'an China
3 State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases Fourth Military Medical University Xi'an China
4 Department of Occupational & Environmental Health and the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health Fourth Military Medical University Xi'an China
* Correspondence
Zhinan Chen and Hai Zhang, Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China.
Email: znchen@fmmu.edu.cn and hzhang@fmmu.eud.cn

09 4 2024
8 2024
7 4 10.1002/ame2.v7.4 Themed Issue: Study on Cardiovascular and Cerebrovascular Diseases 460470
01 2 2024
17 3 2024
© 2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

The mouse genome has a high degree of homology with the human genome, and its physiological, biochemical, and developmental regulation mechanisms are similar to those of humans; therefore, mice are widely used as experimental animals. However, it is undeniable that interspecies differences between humans and mice can lead to experimental errors. The differences in the immune system have become an important factor limiting current immunological research. The application of immunodeficient mice provides a possible solution to these problems. By transplanting human immune cells or tissues, such as peripheral blood mononuclear cells or hematopoietic stem cells, into immunodeficient mice, a human immune system can be reconstituted in the mouse body, and the engrafted immune cells can elicit human‐specific immune responses. Researchers have been actively exploring the development and differentiation conditions of host recipient animals and grafts in order to achieve better immune reconstitution. Through genetic engineering methods, immunodeficient mice can be further modified to provide a favorable developmental and differentiation microenvironment for the grafts. From initially only being able to reconstruct single T lymphocyte lineages, it is now possible to reconstruct lymphoid and myeloid cells, providing important research tools for immunology‐related studies. In this review, we compare the differences in immune systems of humans and mice, describe the development history of human immune reconstitution from the perspectives of immunodeficient mice and grafts, and discuss the latest advances in enhancing the efficiency of human immune cell reconstitution, aiming to provide important references for immunological related researches.

Over recent decades, researchers have been actively exploring the development and differentiation conditions of host recipient animals and grafts in order to achieve better immune reconstitution. The human immune system can be reconstituted in immunodeficient mice by transplanting human peripheral blood mononuclear cells or hematopoietic stem cells, and the engrafted immune cells can elicit human‐specific immune responses. At present, three different types of human immune reconstitution mice have been developed and human lymphoid and myeloid cell‐mediated immune systems have been reconstituted successfully in immunodeficient mice.

hematopoietic stem cell
human immune reconstitution
immune response
immunodeficient mice
peripheral blood mononuclear cell
transplantation
Scientific and Technological Resources Coordination Project of Shaanxi Province2020PT‐002 2022PT‐43 CX‐PT‐18 Special Fund for Military Laboratory AnimalsSYDW_KY (2021)13 State Key Laboratory of Holistic Integrative Management of Gastrointestinal CancersCBSKL2022ZZ28 source-schema-version-number2.0
cover-dateAugust 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:03.09.2024
Bin Y , Ren J , Zhang H , et al. Against all odds: The road to success in the development of human immune reconstitution mice. Anim Models Exp Med. 2024;7 :460‐470. doi:10.1002/ame2.12407
==== Body
pmc1 INTRODUCTION

The mouse has become the most widely used animal in biomedical research due to its small size, fast reproduction, well‐defined genetic background, and ease of manipulation. Over the last 100 years, thousands of different strains of inbred, outbred, hybrid, and mutant mice have been artificially bred for biomedical research 1 ; however, due to the interspecies differences between humans and mice, the experimental results obtained in mice cannot be directly generalized to humans. Thus, it is necessary to develop a model organism that can closely simulate human pathological and physiological responses.

The immune response is an important mechanism for maintaining homeostasis in the body; however, for ethical reasons, the majority of experiments can only be conducted in mice, and the observations of immune responses in mice provide evidence for human immunological reactions. There are differences in immune cell composition, immune cell distribution, and immune molecule expression between humans and mice, thus making it difficult to deduce the overall picture of human immune responses based on results obtained in mice. 2 For example, the first therapeutic antibody drug approved by the U.S. Food and Drug Administration, OKT3, did not induce cytokine storms in mice and monkeys during preclinical studies, but it caused typical cytokine storms in humans. 3 Therefore, the artificial breeding of mice that fully exhibit human immune responses for biomedical research is difficult, and if mice are to be used for biomedical research, the experimental errors caused by interspecies differences must be overcome. Decades ago, researchers attempted to overcome these differences by introducing human genes into mice through transgenic methods or knocking out genes closely related to immune responses in mice; however, it has been shown that the knockout or introduction of single genes cannot completely eliminate these effects. 4 , 5 , 6 Xenotransplantation is an effective method to address the experimental errors caused by interspecies differences. 7 By selecting appropriate human immune tissues or cells and transplanting them into suitable mice, human immune tissues can be engrafted and functionally rebuilt in mice, thus overcoming the differences in immune responses between humans and mice. 8 Researchers have made unremitting efforts over the last few decades, going through multiple stages of development and actively exploring the biological characteristics of donor grafts and host animals. They have successfully transplanted human peripheral blood mononuclear cells (PBMCs) and hematopoietic stem cells (HSCs) into different strains of immunodeficient mice, reconstructing the human immune system in mice. Starting from the initial reconstruction of the human lymphoid immune cells in the microenvironment of mice, it is now possible to reconstruct both lymphoid and myeloid immune cells, solving the current challenges in biomedical research and providing an ideal animal model for immunological research.

2 IMMUNE SYSTEM DIFFERENCES BETWEEN HUMANS AND MICE

Natural selection and artificial breeding are the mechanisms behind the differences in the immune systems of humans and mice. The last common ancestor of humans and mice lived approximately 65–75 million years ago. 9 Comparative genomics studies have found that humans and mice share 80% of their genes, but only 40% of these genes are complete matches, with approximately 300 genes, including 169 immune‐related genes, showing species specificity and differences between the two species. 10 , 11

Humans and mice are mammals, and although there are no significant anatomical differences in the overall structure of their immune organs, there are differences in immune cell composition, immune cell distribution, and immune molecule expression. 2 There is a significant difference in the percentage of lymphocytes and neutrophils in human and mouse peripheral blood. Human peripheral blood has a higher percentage of neutrophils and a lower percentage of lymphocytes, while the opposite is the case in mice. 12 The immunoglobulin types in human and mouse sera are also different. In mice, IgG is divided into four subclasses, namely, IgG1, IgG2a, IgG2b, and IgG3, while in humans, IgG is divided into different subclasses, namely, IgG1, IgG2, IgG3, and IgG4. This difference leads to different binding abilities between different subclasses of IgG and Fc receptors. 13 Although the anatomical structure of the spleen is similar in humans and mice, the distribution of T cells in the white pulp of the spleen differs. T cells in mice are clustered, while in humans, they are scattered in the germinal centers. 14 There are also differences in the composition of immune cells in the epidermis of the skin between humans and mice. Dendritic epidermal γδ T cells (DETCs) are only found in the epidermis of mice, while humans have αβ T cells but no DETCs. 15 , 16 The interspecies differences between humans and mice also determine differences in immune molecule expression and function. Human neutrophils can express defense molecules with antimicrobial effects, while mouse neutrophils do not possess this function. In human neutrophils, FcαRI can mediate immune killing after binding with antibodies, but mouse neutrophils do not express FcαRI; instead, they use Fcα/μR to bind with IgM. 17 Ly49 is an inhibitory receptor for NK and NKT cells in mice, while the inhibitory receptor for human NK cells is KIR, not Ly49. 18 Similarly, there are differences in ligand binding between human and mouse NK cells. Human NKG2D can bind to its ligands MHC‐I and UL16, while mouse NKG2D binds to H‐60 and Rae1β to exert biological effects. 19 , 20 These interspecies differences in immune‐related genes also result in different functions. Mutation of the X‐linked interleukin 2 receptor subunit gamma chain gene (IL2rg, CD132 or γc) affects the development of human T cells and NK cells, but not B cells; however, mutation of the IL2rg gene severely decreases the number of B cells in mice. 21 Similarly, mutation of the IL7R gene inhibits the development of human T cells, but in mice, it affects both T and B cell development. 22 , 23 Interspecies differences between humans and mice also result in different immune response processes. In humans, activation of Th2 cells results in the recruitment of eosinophils and the production of IgE by B cells, which is the main defense mechanism against schistosomiasis; however, mice use Th1 cell‐produced IFN‐γ to combat parasite infection. 24 , 25 IFN‐αβ or IL‐4 combined with anti‐CD23 antibodies can induce human macrophages to produce inducible nitric oxide synthase (iNOS) to resist pathogenic microbial infections, while mouse macrophages can only produce significant levels of iNOS when induced by LPS and IFN‐γ. 26 , 27

The currently available laboratory mice are inbred or transgenic mice that have been artificially bred for a long time and are maintained in an SPF environment. They have lost genetic diversity and are sensitive to the external environment; moreover, the immune differences caused by interspecies differences further limit the range of application of these mice. However, the reconstruction of the human immune system in mice through xenotransplantation can effectively solve the problems encountered in mouse experiments.

3 CHOICE OF RECIPIENT HOST ANIMAL AND DONOR GRAFT

Reconstructing the human immune system in mice through xenotransplantation involves both a donor graft and a recipient host animal. The donor graft from humans should include cells or tissues that are immunologically relevant, while the recipient host animal should be able to accept the donor graft and allow it to proliferate or differentiate in the body. The discovery and application of immunodeficient mice are important milestones in the process of human immune reconstruction. Donor grafts can survive in immunocompromised mice due to their immunodeficiency. The development of immunodeficient mice has progressed from the simplest types, such as nude mice (with T cell deficiency), to the currently used severe combined immunodeficient (SCID) mice, which have severe combined deficiencies in T, B, and NK cell functions. This development has gone through different stages (Figure 1). SCID mice now serve as a suitable host for human immune transplantation.

FIGURE 1 Diagram of immunodeficient mouse development.

3.1 prkdc −/− mice

The discovery of hairless mice with a single T cell deficiency due to a Foxn1 mutation paved the way for studying immunodeficient mice and provided favorable conditions for human xenotransplantation models. 28 , 29 The DNA‐dependent protein kinase (DNA‐PK), encoded by the Prkdc gene, is a critical component of the non‐homologous end joining pathway for repairing double‐strand breaks in DNA during V(D)J recombination. In addition to DNA‐PK, Artemis, Rag1/2, XRCC4 and Ligase IV are also important regulatory genes in the V(D)J recombination process. The complexes consisting of DNA‐PK/ Artemis, Rag1/2, and Ligase IV/XRCC4 complete the repair of double‐strand gaps during V(D)J recombination, generating diverse T and B cell receptors that mediate adaptive immune responses. 30 , 31 , 32 Mutations in any of these genes in the complex result in abnormal V(D)J recombination, leading to impaired T and B cell development; this is also known as SCID. 33 Introducing the mutated Prkdc gene in C.B‐17, C3H, and Beige mice can generate typical SCID animals. 34 , 35 , 36 SCID mice exhibit more severe immune deficiencies than nude mice, making them a preferred model for immune reconstitution studies. Although SCID mice have combined T and B cell deficiencies, their NK cells, macrophages, and complement system function normally. Non‐obese diabetic (NOD) mice, on the other hand, have lower NK cell function, macrophage defects, and complement deficiency. 37 NOD‐SCID mice were generated by crossing NOD mice with C.B‐17/SCID mice, which retained the characteristics of both strains with combined T and B cell deficiencies, as well as low NK cell function, macrophage defects, and complement deficiency 38 (Figure 1). Human immune grafts develop and proliferate better in NOD‐SCID mice compared to SCID mice. The introduction of mutations in key genes involved in the repair of double‐strand gaps in V(D)J recombination, such as Prkdc, Rag1/2, Dclre1c, and Ligase IV, using embryonic stem cell targeting techniques, can also result in severe combined immunodeficiency SCID in mice with impaired T and B cell function. 39 , 40 , 41 , 42

3.2 IL2rg −/− mice

IL2rg encodes a glycoprotein mainly expressed on the surface of memory T cells and NK cells, serving as a common receptor subunit for various important immune factors such as IL‐2, IL‐4, IL‐7, IL‐9, IL‐15, and IL‐21. Janus kinase 3 (JAK3) is one of the crucial kinases that mediate IL‐2 receptor signaling, the interaction between IL2rg and JAK3 regulates the activity of immune cells, either a mutation in the IL2rg or JAK3 gene can cause immune deficiency, characterized by NK cell deficiency, downregulation of cytokine expression, and inhibition of immune cell proliferation and differentiation. 43 , 44 , 45 , 46 IL2rg and JAK3 mutations were introduced into NOD‐SCID mice in order to further enhance immune deficiency in the mice (Figure 1). The resulting NSG (NOD/LtSz‐Prkdcscid Il2rgtm1Wjl/J), NOG (NOD/Shi‐Prkdcscid Il2rgtm1Sug/Jic), and NOD/SCID‐JAK3null mice not only retained the T and B cell deficiency, macrophage defects, and complement deficiency of NOD‐SCID mice, but also exhibited NK cell deficiency and downregulated expression of cytokines IL‐2, IL‐4, IL‐7, IL‐9, IL‐15, and IL‐21 due to the IL2rg mutation. 47 , 48 These mice are more immunodeficient than NOD‐SCID mice, Rag1 or Rag2 mutant mice, thus making them more suitable for human immune system engraftment. Using gene editing technologies such as ZFN, TALEN, and CRISPR/Cas9, severe combined immunodeficient mice with T, B, and NK cell defects, like NCG and BRG mice, can be generated by mutating Prkdc, Rag1/2, Dclre1c, and IL2rg. 49 , 50 Many different strains of SCID mice are currently used for human immune reconstitution, every strain has different biological characteristics, and the efficiency in engrafting human immune cells varies among strains. In general, NOD‐SCID mice with T and B cell defects have lower reconstitution efficiency than NSG, NOG, and BRG mice with combined T, B, and NK cell deficiencies, and the reconstitution effects in BRG mice are less pronounced than in NSG and NOG mice 51 , 52 ; therefore, NSG and NOG mice are currently the most widely used animal models for human immune reconstitution and immune system transplantation research.

3.3 Donor grafts

The thymus, bone marrow, lymph nodes, spleen, and mucosal tissues are the immune organs, where immune cells develop, differentiate, mature, and reside. Immune cells that have matured in the immune organs circulate through the bloodstream and play a part in the immune response; therefore, immune organs and peripheral blood have become the main choice for transplantation in the process of human immune reconstitution. In the early stages of human immune reconstitution, fetal thymus, bone marrow, lymph nodes, and other tissues were often transplanted, 53 , 54 but obtaining immune organs was difficult and the transplantation technique was demanding. Later, adult peripheral blood became a common choice for transplantation. PBMCs are a mixed population of mononuclear cells with a single nucleus found in peripheral blood, which includes T lymphocytes, B lymphocytes, NK cells, monocytes, phagocytes, and dendritic cells that are produced in the thymus, bone marrow, spleen, and other immune organs. 55 The immune cells in PBMCs are mostly mature cells, and following transplantation, some of them can directly proliferate in the immunodeficient mice, thus partially reconstructing the human immune system.

CD34+ HSCs obtained from umbilical cord blood, the embryonic liver, mobilized peripheral blood, or bone marrow are precursors for all immune cells and possess the ability to self‐renew and differentiate into immune cells. 56 Following transplantation, pluripotent CD34+ cells show different differentiation abilities, depending on the host animal, and can differentiate into different types of human immune cells for immune reconstitution.

4 HUMAN IMMUNE RECONSTITUTION MICE

Humanized mice for immune reconstitution can be classified into three categories, namely, hu‐PBL, hu‐HSC, and hu‐BLT, based on the source of the graft and the host animal (Figure 2).

FIGURE 2 Diagram of human immune reconstitution mouse classification.

4.1 hu‐PBL immune reconstitution mice

Human PBMCs or human peripheral blood lymphocytes (hu‐PBLs) are easy to obtain and manipulate. They have already differentiated and matured in the human body, so they can be directly transplanted into immunodeficient mice for rapid reconstruction of human immune cells 57 (Figure 2). This is a relatively simple and economical model, providing humanized mice with a human immune system. In the early stages, the PBMCs or lymphocytes were often transplanted into SCID mice, but with the discovery and application of NSG or NOG mice, which have higher degrees of immunodeficiency, these two types of mice are now commonly used for hu‐PBL reconstitution. The presence of human CD45+ T cells can be detected as early as 2 weeks after hu‐PBL transplantation. After 3 weeks, human CD45+CD3+ cells, including a large number of CD4+ and CD8+ T cell subsets, proliferate rapidly. Further analysis revealed an increase in the number of CD45RO+CD27− effector T cells in the CD4+ and CD8+ T cell subsets, while the ratios of initial CD45RO−CD27+ T cells/CD45RO+CD27+ memory T cells and central CD45RO+CD27+CD62L+ memory T cells/CD45RO+CD27+CD62L− effector memory T cells were both decreased. This indicates that in hu‐PBL‐SCID mice, the human T cell subset mainly comprises central memory T cells, while other T cell subsets such as FOXP3+CD25+CD127low regulatory T cells are not found to proliferate. 58 , 59 , 60 Human T cell subsets often colonize and proliferate in the peripheral blood, thymus, spleen, liver, and lymph nodes of mice, and the presence of different human T cell subsets can be detected in these tissues. 60 , 61 In hu‐PBL mice, only the proliferation of different types of human T cells can be detected, while CD19+ B cells can only be maintained at very low levels for a short time in the bone marrow and spleen of these mice. 62 Human NK cells and other myeloid immune cells, such as macrophages, dendritic cells, and granulocytes, cannot proliferate in the body of hu‐PBL mice. 63 Due to the differences in human and mouse MHC antigens, the transplantation of human PBMCs often causes graft‐versus‐host disease (GVHD) in hu‐PBL mice in the short term, leading to weight loss, a hunching posture, hair loss, and decreased activity; GVHD can even result in death, thus shortening the experimental window. 64 , 65 , 66 Therefore, hu‐PBL mice are only used to observe T cell‐mediated immune responses and conduct short‐term experimental studies.

4.2 hu‐HSC immune reconstitution mice

CD34+ HSCs have the ability to differentiate into multiple lineages, and transplantation into immunocompromised mice with the help of the animal's microenvironment has become an important method for human immune reconstruction (Figure 2). HSCs used for transplantation are typically sourced from fetal liver, umbilical cord blood, bone marrow, or G‐CSF‐mobilized peripheral blood. 67 , 68 Notably, the source of HSCs can influence the function of human T cells that develop in the transplanted mice. T cells derived from CD34+ HSCs from fetal sources have higher immunotolerance compared to those from adult sources. 69 Following transplantation into NSG or NOG mice, HSCs can partially reconstitute the human immune system within 10–12 weeks. Human innate immune response cells, adaptive immune response cells, and a small number of red blood cells and platelets can be detected in the mice. 70 , 71 , 72 Unlike PBMC transplantation, which only allows the reconstitution of human T cells, in hu‐HSC mice, various types of human immune cells can be detected. In addition, HSCs from CD34+ HSC transplants can differentiate into different lineages of immune cells in SCID mice, leading to a lower rejection response from the mouse immune system and delayed development of GVHD 71 ; however, hu‐HSC mice are not an ideal animal model for immune reconstruction, as human myeloid cells, such as macrophages, dendritic cells, and NK cells do not develop fully in the mice. This results in decreased production of antigen‐specific IgGs and reduced HLA restriction. In light of these characteristics, hu‐HSC mice are suitable for conducting experiments that require long research periods and observation of various immune responses.

4.3 hu‐BLT immune reconstitution mice

T cell development depends on the thymic microenvironment, but immunodeficient mice have severe thymus degeneration, which is one of the reasons for the low efficiency of immune reconstruction. Transplantation of fetal thymic and liver tissues into immunodeficient mice under the renal capsule creates an artificial thymic microenvironment, which overcomes the problem of impaired T cell development due to thymus degeneration in mice 73 (Figure 2). Based on this principle, researchers have created BLT mice to improve immune reconstruction efficiency. BLT mice are created by simultaneous transplantation of fetal thymic and liver tissues into NSG or NOG mice under the renal capsule, followed by injection of CD34+ HSCs to reconstitute the human immune system. The humanized thymus in BLT mice provides an ideal environment for T cell development, education, and selection, resulting in HLA‐restricted T cells. Further, this mouse model can reconstitute human myeloid cells, including monocytes, granulocytes, and the mucosal immune system. 74 , 75

Transplanted human tissues in recipient mice establish a complete human hematopoietic microenvironment, enhancing the multi‐lineage reconstitution of human hematopoietic cells. Notably, a functional and complete human immune system, including T cells, B cells, and dendritic cells, is developed. These mice also produce high levels of human IgM and IgG antibodies. The development of T cells relies on selection in the human thymus. BLT mice, which contain diverse HLA‐restricted T cells, can establish effective adaptive immune responses; therefore, BLT mice are often used in research related to adaptive immune responses, such as HIV infection. 76 The use of BLT mouse models is limited by the availability of human embryonic tissues, and due to the positive selection in the thymus being specific to human T cells, T cells with mouse MHC specificity cannot be eliminated. As a result, hu‐BLT‐SCID mice are more prone to developing GVHD than other humanized mouse models. 77

5 OPTIMIZATION OF HUMAN IMMUNE RECONSTITUTION EFFECT

5.1 Improvements in immunodeficient mice

5.1.1 Promoting multidirectional differentiation of HSCs

HSCs are a type of progenitor cell that can self‐renew, differentiate, and regenerate into various types of blood cells. The regulation, proliferation, and differentiation of HSCs involve a series of hematopoietic growth factors. Positive regulators such as stem cell factor (SCF), FLT3, colony‐stimulating factors (CSFs), IL‐2, IL‐3, IL‐6, IL‐15, and thrombopoietin (TPO) promote HSC differentiation, while negative regulators such as TGF‐β, TNF‐α, β, and chemokines inhibit HSC differentiation. 78 , 79 , 80 Positive regulators bind to receptors on HSCs, activating intracellular signaling pathways such as the ERK, JNK, and TKR pathways, inducing the division and proliferation of hematopoietic progenitor cells, and promoting the transition of HSCs from the G0 phase to the G1 phase, accelerating HSC proliferation and differentiation. 81 , 82 Negative regulators such as TGF‐β induce HSCs to enter the G0 phase, inhibiting HSC proliferation and differentiation. 83 Under the influence of positive regulators, HSCs can differentiate into various blood cell lineages, including myeloid cells (monocytes, macrophages, granulocytes, red blood cells, megakaryocytes/platelets, and dendritic cells) and lymphoid cells (T, B, and NK cells).

As mentioned above, following the transplantation of human HSCs into immunodeficient mice, the mice lack the microenvironment necessary for the proliferation and differentiation of human HSCs. Consequently, HSCs are unable to differentiate into lymphoid NK cells and myeloid cells such as granulocytes and macrophages; however, researchers have used genetic engineering methods to introduce positive regulatory factors that regulate HSC differentiation into the mice (Figure 1), thereby improving the developmental microenvironment for human HSCs and enabling their differentiation into various lineages of immune cells. IL‐2 is an important cytokine that induces the proliferation of NK cells; it activates various kinase pathways, increases NK cell activity, and promotes NK cell proliferation. IL‐15 upregulates the expression of surface receptors on NK cells and also promotes the expansion of CD56+ cells. 84 By expressing human IL‐2 and IL‐15 in NOG or NSG mice, researchers have overcome the limitations of HSC differentiation into NK cells observed in prior studies. The differentiation and proliferation of CD56+ NK cells in the peripheral blood and spleen of these mice are more than 10 times higher than that in NOG mice. Further, these NK cells express various receptors, such as NKp30, NKp44, NKp46, NKG2D, and CD94, and produce cytotoxic factors such as perforin and granzyme upon stimulation. 84 , 85 , 86

Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), SCF, IL‐3, and TPO are cytokines that are essential for the differentiation of CD34+ HSCs into granulocytes. MISTRG, NSG‐SGM3, or NOG‐EXL mice expressing these cytokines can generate not only lymphoid T and B cells but also myeloid cells such as granulocytes, macrophages, and dendritic cells (Figure 1). In sum, the development of human immune reconstitution mouse models has undergone a complex process, from the simple transplantation of PBMCs to the development of CD34+ HSC‐based models capable of reconstituting both innate and adaptive immune cells. 87 , 88 , 89 These models involved continuous modifications to provide the necessary microenvironment for HSC differentiation. Ultimately, the transplanted CD34+ HSCs can reconstitute multi‐lineage immune cells, providing valuable tools for immunological research.

HLA plays a pivotal part in the education of T progenitor cells. The low efficiency of human T cell reconstitution in immunodeficient mice is believed to be related to the lack of human HLA expression in these mice 90 ; however, by expressing HLA‐DR4, HLA‐A2, and other HLA molecules in immunodeficient mice, transplanted human HSCs can differentiate into CD4+ helper T cells, antigen‐specific CD8+ T cells, and functional B cells. 91 , 92 , 93 , 94

5.1.2 Increasing the degree of immunodeficiency

Currently, commonly used human immune‐reconstituted mice are constructed based on mice with combined T, B, and NK cell deficiencies; however, the deficiency of T, B, and NK cells alone is not sufficient to ensure the survival of human grafts in mice, as other types of immune cells or immune molecules are still key factors influencing immune reconstitution. FLT3L, a hematopoietic growth factor, can promote the development of hematopoietic precursor cells into dendritic cells and enhance the survival and proliferation of dendritic cells. However, normal FLT3L expression in the bone marrow of immunodeficient mice can affect the effectiveness of immune reconstitution. Immunodeficient mice with the Flk2/Flt3 molecule knocked out, also known as BRGF mice, not only have impaired development of their own dendritic cells but also promote the reconstitution of human dendritic cells following transplantation of CD34+ HSCs, thereby improving the efficiency of human T cell and NK cell reconstitution. 95 The binding of the macrophage‐expressed Sirpα receptor with its ligand CD47 mediates the generation of inhibitory ‘don't eat me’ signals, which inhibits the phagocytic activity of macrophages against target cells. 96 , 97 The Sirpα in NOD background mice exhibits structural similarity to the human form and is able to bind human CD47. As a result, introducing NOD mouse Sirpα into BRGF mice can reduce the phagocytic activity of macrophages and enhance transplantation efficiency (Figure 1). CD34+ HSCs transplanted into these mice can differentiate into functional immune cells without developing GVHD. 98 , 99 , 100

5.1.3 Reducing the occurrence of GVHD

Although GVHD after CD34+ HSC transplantation appears later and with milder reactions compared to PBMC transplantation, GVHD resulting from PBMC transplantation is the most common issue in immune reconstitution, severely limiting the application of such models. Different factors contribute to the occurrence of GVHD, including animal pre‐treatment methods (such as irradiation), the PBMC inoculation dose, and host immune responses. The Prkdc is a radiosensitive gene, and immunodeficient mice based on Prkdc gene mutations are commonly irradiated with low doses of γ‐rays to reduce GVHD and improve the engraftment rate of human immune cells. 101 However, loss of c‐kit function impairs endogenous mouse hematopoietic stem cells, allowing engraftment of human HSC without irradiation. Thus, NSG or NOG mice with a c‐kit mutation (NSGW41 mice) can achieve a higher reconstitution efficiency of human immune cells after HSC transplantation free from the need of γ‐ray irradiation. 102 In PBMC transplantation, the occurrence of GVHD resulting from the recipient mouse's MHC antigen recognition of donor T cells leads to a significantly shorter experimental window, thus impacting experimental results. Immunodeficient mice with mutations in MHC‐I and/or MHC‐II subunits (β2‐microglobulin) and H2‐Ab1 show a significant reduction in GVHD occurrence, thus extending the experimental window 59 , 103 , 104 (Figure 1). Further, in TKO mice with CD47 knockout, the onset of GVHD after human PBMC transplantation is delayed. 98

5.2 Improvement of the microenvironment for HSC development

5.2.1 Lymph nodes

Lymph nodes are the primary sites for the residence of mature T and B cells; however, immunodeficient mice with IL2rg knockout have underdeveloped lymph nodes, which affects the development of transplanted human T and B cells. By specifically re‐expressing the IL2rg gene or thymic stromal cell‐derived lymphopoietin (TSLP) in lymphoid tissues of immunodeficient mice, the development of lymph nodes can be promoted, providing suitable developmental niches for immune cells. As a result, human T cells can reside in the lymph nodes of the mice following immune reconstitution, with a predominance of residence in the intestinal lymph nodes. In addition, they can generate antigen‐specific IgG antibodies. 105 , 106

5.2.2 Hematopoietic niche

The bone marrow microenvironment is composed of mesenchymal stem cells (MSCs) and differentiated cells such as osteoblasts, osteoclasts, vascular endothelial cells, stromal cells, and hematopoietic cells. 107 MSCs play a pivotal part in providing essential support for self‐renewal and differentiation of HSCs. MSCs can directly interact with HSCs through adhesion molecules on their cell membrane or regulate HSC differentiation and maturation through the secretion of various cytokines such as IL‐6, IL‐11, LIF, G‐CSF, SCF, and GM‐CSF. 108 , 109 In vitro co‐culture of MSCs and HSCs effectively enhances HSC proliferation, while in vivo co‐transplantation enhances HSC engraftment and differentiation, with a higher engraftment of CD13+ myeloid lineage cells and earlier appearance of CD19+ B cells. 110 , 111 , 112 MSCs overexpressing PDGFB have a more pronounced regulatory effect on HSCs, promoting HSC engraftment and maintaining their self‐renewal capacity, as compared to wild‐type MSCs. 113 , 114 In addition, co‐infusion of MSCs and allogeneic HSCs can prevent and alleviate GVHD, facilitate HSC engraftment, and accelerate hematopoietic reconstitution. 114 , 115 The antioxidant N‐acetyl‐L‐cysteine (NAC) can reduce ROS levels in the bone marrow of NOD‐SCID mice, improve the bone marrow hematopoietic microenvironment, and enhance HSC engraftment efficiency. NAC‐treated NOD‐SCID mice exhibit a 10.8‐fold higher efficiency in immune reconstitution compared to untreated mice. 116

5.2.3 Organoids

Although thymus and bone marrow transplantation provide good strategies for immune reconstitution in humans, ethical issues limit the widespread application of bone marrow–liver–thymus (BLT) mice. Researchers have developed thymic organoid as a substitute for the human thymus in order to address this. In vitro cultured induced pluripotent stem cells (iPSC) can be directed to differentiate into functional thymic epithelial progenitor cells, supporting de novo construction of a T cell compartment in humanized mice engrafted with iPSC‐derived thymus organoids after CD34+ HSCs implantation. 117 , 118 , 119 The transplantation of a human bone marrow MSC‐derived ossicle‐like organoid under the skin of immunodeficient mice can establish a humanized bone marrow microenvironment. The humanized bone marrow microenvironment provides a suitable homing and engraftment site for human HSCs compared to mouse bone marrow, thus promoting their differentiation and proliferation and significantly improving the engraftment efficiency of HSCs. 120

6 PROSPECTS

After decades of development, researchers have successfully reconstituted the human immune system in immunodeficient mice by transplanting PBMCs or HSCs. These humanized immune‐reconstituted mice overcome interspecies differences and provide important tools for immunology‐related research; however, it is undeniable that current humanized immune‐reconstituted mice still have limitations, such as a single‐lineage immune cell repertoire, a high risk of GVHD after PBMC transplantation, and a long HSC differentiation period. Regarding the host animal, SCID mice are currently the most suitable host animal. Developing genetically engineered mice that differ from the commonly used SCID mice may be an important approach to improve the efficiency of immune reconstitution. Regarding the graft, MSC co‐transplantation with HSCs can effectively enhance the HSC differentiation capacity, and the use of organoids provides a superior microenvironment for HSC differentiation. Therefore, MSC co‐transplantation with HSCs or simultaneous transplantation of HSCs and organoids in immunodeficient mice may be important strategies for improving immune reconstitution efficiency in the future.

AUTHOR CONTRIBUTIONS

Yixiao Bin conceived and wrote the original draft of this manuscript, Hai Zhang and Zhinan Chen revised it. All authors critically read and contributed to the manuscript, and approved its final version.

FUNDING INFORMATION

This work was supported by Scientific and Technological Resources Coordination Project of Shaanxi Province (2020PT‐002, 2022PT‐43, 2023‐CX‐PT‐18), Special Fund for Military Laboratory Animals (SYDW_KY (2021)13) and State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers (CBSKL2022ZZ28).

CONFLICT OF INTEREST STATEMENT

Hai Zhang is an editorial board member of AMEM and co‐author of this article. To minimize bias, he was excluded from all editorial decision making related to the acceptance of this article for publication. The authors declare that there is no conflict of interest regarding the publication of this article.

ETHICS STATEMENT

None.

ACKNOWLEDGMENTS

None.
==== Refs
REFERENCES

1 Casellas J . Inbred mouse strains and genetic stability: a review. Animal. 2011;5 (1 ):1‐7.22440695
2 Masopust D , Sivula CP , Jameson SC . Of mice, dirty mice, and men: using mice to understand human immunology. J Immunol. 2017;199 (2 ):383‐388.28696328
3 Bugelski PJ , Achuthanandam R , Capocasale RJ , Treacy G , Bouman‐Thio E . Monoclonal antibody‐induced cytokine‐release syndrome. Expert Rev Clin Immunol. 2009;5 (5 ):499‐521.20477639
4 Vitiello A , Marchesini D , Furze J , Sherman LA , Chesnut RW . Analysis of the HLA‐restricted influenza‐specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human‐mouse class I major histocompatibility complex. J Exp Med. 1991;173 (4 ):1007‐1015.1706750
5 Ito K , Bian HJ , Molina M , et al. HLA‐DR4‐IE chimeric class II transgenic, murine class II‐deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med. 1996;183 (6 ):2635‐2644.8676084
6 Zhai Y , Chen L , Zhao Q , et al. Cysteine carboxyethylation generates neoantigens to induce HLA‐restricted autoimmunity. Science. 2023;379 (6637 ):eabg2482.36927018
7 Saito Y , Matsumoto N , Yamanaka S , Yokoo T , Kobayashi E . Beneficial impact of interspecies chimeric renal organoids against a xenogeneic immune response. Front Immunol. 2022;13 :848433.35242145
8 Thomsen M , Galvani S , Canivet C , Kamar N , Böhler T . Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology. 2008;246 (1 ):18‐23.18055093
9 Emes RD , Goodstadt L , Winter EE , Ponting CP . Comparison of the genomes of human and mouse lays the foundation of genome zoology. Hum Mol Genet. 2003;12 (7 ):701‐709.12651866
10 Waterston RH , Birney E , Rogers J , et al. Initial sequencing and comparative analysis of the mouse genome. Nature (London). 2002;420 (6915 ):520‐562.12466850
11 Medetgul‐Ernar K , Davis MM . Standing on the shoulders of mice. Immunity. 2022;55 (8 ):1343‐1353.35947979
12 Doeing DC , Borowicz JL , Crockett ET . Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol. 2003;3 (1 ):3.12971830
13 Martin RM , Lew AM . Is IgG2a a good Th1 marker in mice? Immunol Today. 1998;19 (1 ):49.
14 Lewis SM , Williams A , Eisenbarth SC . Structure and function of the immune system in the spleen. Sci Immunol. 2019;4 (33 ):eaau6085.30824527
15 Johnson MD , Witherden DA , Havran WL . The role of tissue‐resident T cells in stress surveillance and tissue maintenance. Cells. 2020;9 (3 ):686.32168884
16 Elbe A , Foster CA , Stingl G . T‐cell receptor alpha beta and gamma delta T cells in rat and human skin–are they equivalent? Semin Immunol. 1996;8 (6 ):341‐349.8961385
17 Monteiro RC , Van De Winkel JG . IgA Fc receptors. Annu Rev Immunol. 2003;21 :177‐204.12524384
18 Lanier LL . NK cell receptors. Annu Rev Immunol. 1998;16 :359‐393.9597134
19 Lodoen M , Ogasawara K , Hamerman JA , et al. NKG2D‐mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med. 2003;197 (10 ):1245‐1253.12756263
20 Kegasawa T , Tatsumi T , Yoshioka T , et al. Soluble UL16‐binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Biochem Biophys Res Commun. 2019;517 (1 ):84‐88.31303272
21 Fischer A , Cavazzana‐Calvo M , De Saint BG , et al. Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol. 1997;15 :93‐124.9143683
22 Peschon JJ , Morrissey PJ , Grabstein KH , et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor‐deficient mice. J Exp Med. 1994;180 (5 ):1955‐1960.7964471
23 Roifman CM , Zhang J , Chitayat D , Sharfe N . A partial deficiency of interleukin‐7R alpha is sufficient to abrogate T‐cell development and cause severe combined immunodeficiency. Blood. 2000;96 (8 ):2803‐2807.11023514
24 Hagan P . IgE and protective immunity to helminth infections. Parasite Immunol. 1993;15 (1 ):1‐4.8433850
25 Pearce EJ , Sher A . Functional dichotomy in the CD4+ T cell response to Schistosoma mansoni. Exp Parasitol. 1991;73 (1 ):110‐116.1711476
26 Bogdan C . Nitric oxide and the immune response. Nat Immunol. 2001;2 (10 ):907‐916.11577346
27 Weinberg JB . Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med. 1998;4 (9 ):557‐591.9848075
28 Flanagan SP . ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet Res. 1966;8 (3 ):295‐309.5980117
29 Pantelouris EM . Absence of thymus in a mouse mutant. Nature. 1968;217 (5126 ):370‐371.5639157
30 Bassing CH , Swat W , Alt FW . The mechanism and regulation of chromosomal V(D)J recombination. Cell. 2002;109 (Suppl ):S45‐S55.11983152
31 Chen X , Xu X , Chen Y , et al. Structure of an activated DNA‐PK and its implications for NHEJ. Mol Cell. 2021;81 (4 ):801‐810.33385326
32 Niewolik D , Schwarz K . Physical ARTEMIS:DNA‐PKcs interaction is necessary for V(D)J recombination. Nucleic Acids Res. 2022;50 (4 ):2096‐2110.35150269
33 de Villartay JP . Congenital defects in V(D)J recombination. Br Med Bull. 2015;114 (1 ):157‐167.25987660
34 Bosma GC , Custer RP , Bosma MJ . A severe combined immunodeficiency mutation in the mouse. Nature. 1983;301 (5900 ):527‐530.6823332
35 Mcelwee KJ , Boggess D , King LJ , Sundberg JP . Experimental induction of alopecia areata‐like hair loss in C3H/HeJ mice using full‐thickness skin grafts. J Invest Dermatol. 1998;111 (5 ):797‐803.9804341
36 Kenney LL , Shultz LD , Greiner DL , Brehm MA . Humanized mouse models for transplant immunology. Am J Transplant. 2016;16 (2 ):389‐397.26588186
37 Kataoka S , Satoh J , Fujiya H , et al. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes. 1983;32 (3 ):247‐253.6298042
38 Prochazka M , Gaskins HR , Shultz LD , Leiter EH . The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA. 1992;89 (8 ):3290‐3294.1373493
39 Pannicke U , Ma Y , Hopfner KP , Niewolik D , Lieber MR , Schwarz K . Functional and biochemical dissection of the structure‐specific nuclease ARTEMIS. EMBO J. 2004;23 (9 ):1987‐1997.15071507
40 Mombaerts P , Iacomini J , Johnson RS , Herrup K , Tonegawa S , Papaioannou VE . RAG‐1‐deficient mice have no mature B and T lymphocytes. Cell. 1992;68 (5 ):869‐877.1547488
41 Shinkai Y , Rathbun G , Lam KP , et al. RAG‐2‐deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68 (5 ):855‐867.1547487
42 Goldman JP , Blundell MP , Lopes L , Kinnon C , di Santo JP , Thrasher AJ . Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol. 1998;103 (2 ):335‐342.9827902
43 O'Shea JJ , Pesu M , Borie DC , Changelian PS . A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004;3 (7 ):555‐564.15232577
44 Giliani S , Mella P , Savoldi G , Mazzolari E . Cytokine‐mediated signalling and early defects in lymphoid development. Curr Opin Allergy Clin Immunol. 2005;5 (6 ):519‐524.16264332
45 Liao W , Lin JX , Leonard WJ . IL‐2 family cytokines: new insights into the complex roles of IL‐2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23 (5 ):598‐604.21889323
46 Goldberg L , Simon AJ , Lev A , et al. Atypical immune phenotype in severe combined immunodeficiency patients with novel mutations in IL2RG and JAK3. Genes Immun. 2020;21 (5 ):326‐334.32921793
47 Shultz LD , Lyons BL , Burzenski LM , et al. Human lymphoid and myeloid cell development in NOD/LtSz‐scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174 (10 ):6477‐6489.15879151
48 Koyanagi Y , Tanaka Y , Kira J , et al. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu‐PBL‐immunodeficient mouse strain. J Virol. 1997;71 (3 ):2417‐2424.9032379
49 Zhao Y , Liu P , Xin Z , et al. Biological characteristics of severe combined immunodeficient mice produced by CRISPR/Cas9‐mediated Rag2 and IL2rg mutation. Front Genet. 2019;10 :401.31134127
50 Bin Y , Wei S , Chen R , et al. Dclre1c‐mutation‐induced immunocompromised mice are a novel model for human xenograft research. Biomol Ther. 2024;14 (2 ):180‐194.
51 Brehm MA , Cuthbert A , Yang C , et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol. 2010;135 (1 ):84‐98.20096637
52 Ito R , Takahashi T , Katano I , Ito M . Current advances in humanized mouse models. Cell Mol Immunol. 2012;9 (3 ):208‐214.22327211
53 Kyoizumi S , Baum CM , Kaneshima H , McCune J , Yee EJ , Namikawa R . Implantation and maintenance of functional human bone marrow in SCID‐hu mice. Blood. 1992;79 (7 ):1704‐1711.1558966
54 Frey JR , Ernst B , Surh CD , Sprent J . Thymus‐grafted SCID mice show transient thymopoiesis and limited depletion of V beta 11+ T cells. J Exp Med. 1992;175 (4 ):1067‐1071.1532413
55 Diaz I . Rules of thumb to obtain, isolate, and preserve porcine peripheral blood mononuclear cells. Vet Immunol Immunopathol. 2022;251 :110461.35870231
56 Hughes MR , Canals HD , Cait J , et al. A sticky wicket: defining molecular functions for CD34 in hematopoietic cells. Exp Hematol. 2020;86 :1‐14.32422232
57 Pearson T , Greiner DL , Shultz LD . Creation of “humanized” mice to study human immunity. Curr Protoc Immunol. 2008;CHAPTER: Unit–15:21.
58 King MA , Covassin L , Brehm MA , et al. Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009;157 (1 ):104‐118.19659776
59 Brehm MA , Kenney LL , Wiles MV , et al. Lack of acute xenogeneic graft‐ versus‐host disease, but retention of T‐cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019;33 (3 ):3137‐3151.30383447
60 Ali N , Flutter B , Sanchez RR , et al. Xenogeneic graft‐versus‐host‐disease in NOD‐scid IL‐2Rgammanull mice display a T‐effector memory phenotype. PLoS One. 2012;7 (8 ):e44219.22937164
61 Holguin L , Echavarria L , Burnett JC . Novel humanized peripheral blood mononuclear cell mouse model with delayed onset of graft‐versus‐host disease for preclinical HIV research. J Virol. 2022;96 (3 ):e0139421.34818071
62 Yanagawa S , Tahara H , Shirouzu T , et al. Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA). PLoS One. 2021;16 (2 ):e0236614.33544740
63 Shultz LD , Brehm MA , Garcia‐Martinez JV , Greiner DL . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12 (11 ):786‐798.23059428
64 Tary‐Lehmann M , Lehmann PV , Schols D , Roncarolo MG , Saxon A . Anti‐SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu‐PBL‐SCID chimeras. J Exp Med. 1994;180 (5 ):1817‐1827.7964463
65 Mosier DE . Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. Adv Immunol. 1991;50 :303‐325.1950798
66 Pino S , Brehm MA , Covassin‐Barberis L , et al. Development of novel major histocompatibility complex class I and class II‐deficient NOD‐SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft‐versus‐host disease. Methods Mol Biol. 2010;602 :105‐117.20012395
67 Beksac M , Yurdakul P . How to improve cord blood engraftment? Front Med (Lausanne). 2016;3 :7.26925402
68 Fomin ME , Beyer AI , Muench MO . Human fetal liver cultures support multiple cell lineages that can engraft immunodeficient mice. Open Biol. 2017;7 (12 ):170108‐170114.29237808
69 Mold JE , Venkatasubrahmanyam S , Burt TD , et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science. 2010;330 (6011 ):1695‐1699.21164017
70 Cheng H , Zheng Z , Cheng T . New paradigms on hematopoietic stem cell differentiation. Protein Cell. 2020;11 (1 ):34‐44.31201709
71 Kim SS , Kumar P , Ye C , Shankar P . Humanized mice for studying human leukocyte integrins in vivo. Methods Mol Biol. 2012;757 :509‐521.21909931
72 Rongvaux A , Takizawa H , Strowig T , et al. Human hemato‐lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol. 2013;31 :635‐674.23330956
73 Lan P , Tonomura N , Shimizu A , Wang S , Yang YG . Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006;108 (2 ):487‐492.16410443
74 Stoddart CA , Maidji E , Galkina SA , et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD‐scid IL‐2Rgamma(−/−) (NSG) BLT mice. Virology. 2011;417 (1 ):154‐160.21684569
75 Roy CN , Shu ST , Kline C , Rigatti L , Smithgall TE , Ambrose Z . Use of pediatric thymus to humanize mice for HIV‐1 mucosal transmission. Sci Rep. 2023;13 (1 ):17067.37816950
76 Garcia‐Beltran WF , Claiborne DT , Maldini CR , et al. Innate immune reconstitution in humanized bone marrow‐liver‐thymus (HuBLT) mice governs adaptive cellular immune function and responses to HIV‐1 infection. Front Immunol. 2021;12 :667393.34122425
77 Greenblatt MB , Vrbanac V , Tivey T , Tsang K , Tager AM , Aliprantis AO . Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One. 2012;7 (9 ):e44664.22957096
78 Ivanovic Z . Interleukin‐3 and ex vivo maintenance of hematopoietic stem cells: facts and controversies. Eur Cytokine Netw. 2004;15 (1 ):6‐13.15217747
79 Drexler HG . Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996;10 (4 ):588‐599.8618433
80 Richter R , Forssmann W , Henschler R . Current developments in mobilization of hematopoietic stem and progenitor cells and their interaction with niches in bone marrow. Transfus Med Hemother. 2017;44 (3 ):151‐164.28626366
81 Wang W , Zhang Y , Dettinger P , et al. Cytokine combinations for human blood stem cell expansion induce cell‐type‐ and cytokine‐specific signaling dynamics. Blood. 2021;138 (10 ):847‐857.33988686
82 Rausch O , Marshall CJ . Cooperation of p38 and extracellular signal‐regulated kinase mitogen‐activated protein kinase pathways during granulocyte colony‐stimulating factor‐induced hemopoietic cell proliferation. J Biol Chem. 1999;274 (7 ):4096‐4105.9933603
83 Wang X , Dong F , Zhang S , et al. TGF‐beta1 negatively regulates the number and function of hematopoietic stem cells. Stem Cell Reports. 2018;11 (1 ):274‐287.29937145
84 Pillet AH , Theze J , Rose T . Interleukin (IL)‐2 and IL‐15 have different effects on human natural killer lymphocytes. Hum Immunol. 2011;72 (11 ):1013‐1017.21925225
85 Katano I , Takahashi T , Ito R , et al. Predominant development of mature and functional human NK cells in a novel human IL‐2‐producing transgenic NOG mouse. J Immunol. 2015;194 (7 ):3513‐3525.25712215
86 Aryee KE , Burzenski LM , Yao LC , et al. Enhanced development of functional human NK cells in NOD‐scid‐IL2rg(null) mice expressing human IL15. FASEB J. 2022;36 (9 ):e22476.35959876
87 Rongvaux A , Willinger T , Martinek J , et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32 (4 ):364‐372.24633240
88 Wunderlich M , Chou FS , Link KA , et al. AML xenograft efficiency is significantly improved in NOD/SCID‐IL2RG mice constitutively expressing human SCF, GM‐CSF and IL‐3. Leukemia. 2010;24 (10 ):1785‐1788.20686503
89 Ito R , Takahashi T , Katano I , et al. Establishment of a human allergy model using human IL‐3/GM‐CSF‐transgenic NOG mice. J Immunol. 2013;191 (6 ):2890‐2899.23956433
90 Watanabe Y , Takahashi T , Okajima A , et al. The analysis of the functions of human B and T cells in humanized NOD/shi‐scid/gammac(null) (NOG) mice (hu‐HSC NOG mice). Int Immunol. 2009;21 (7 ):843‐858.19515798
91 Majji S , Wijayalath W , Shashikumar S , et al. Differential effect of HLA class‐I versus class‐II transgenes on human T and B cell reconstitution and function in NRG mice. Sci Rep. 2016;6 :28093.27323875
92 Majji S , Wijayalath W , Shashikumar S , Brumeanu TD , Casares S . Humanized DRAGA mice immunized with plasmodium falciparum sporozoites and chloroquine elicit protective pre‐erythrocytic immunity. Malar J. 2018;17 (1 ):114.29540197
93 Labarthe L , Henriquez S , Lambotte O , et al. Frontline science: exhaustion and senescence marker profiles on human T cells in BRGSF‐A2 humanized mice resemble those in human samples. J Leukoc Biol. 2020;107 (1 ):27‐42.31378988
94 Billerbeck E , Horwitz JA , Labitt RN , et al. Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA‐transgenic human immune system mice. J Immunol. 2013;191 (4 ):1753‐1764.23833235
95 Li Y , Mention JJ , Court N , et al. A novel Flt3‐deficient HIS mouse model with selective enhancement of human DC development. Eur J Immunol. 2016;46 (5 ):1291‐1299.26865269
96 Takenaka K , Prasolava TK , Wang JC , et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8 (12 ):1313‐1323.17982459
97 Legrand N , Huntington ND , Nagasawa M , et al. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T‐ and natural killer‐ (NK) cell homeostasis in vivo. Proc Natl Acad Sci USA. 2011;108 (32 ):13224‐13229.21788504
98 Lavender KJ , Pang WW , Messer RJ , et al. BLT‐humanized C57BL/6 Rag2−/−gammac−/‐CD47−/− mice are resistant to GVHD and develop B‐ and T‐cell immunity to HIV infection. Blood. 2013;122 (25 ):4013‐4020.24021673
99 Lopez‐Lastra S , Masse‐Ranson G , Fiquet O , et al. A functional DC cross talk promotes human ILC homeostasis in humanized mice. Blood Adv. 2017;1 (10 ):601‐614.29296702
100 Jinnouchi F , Yamauchi T , Yurino A , et al. A human SIRPA knock‐in xenograft mouse model to study human hematopoietic and cancer stem cells. Blood. 2020;135 (19 ):1661‐1672.32206775
101 Cowan MJ , Gennery AR . Radiation‐sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation–what to do? J Allergy Clin Immunol. 2015;136 (5 ):1178‐1185.26055221
102 Cosgun KN , Rahmig S , Mende N , et al. Kit regulates HSC engraftment across the human‐mouse species barrier. Cell Stem Cell. 2014;15 (2 ):227‐238.25017720
103 Chen SS , Wang H , Xing J , et al. NCG‐MHC‐dKO mice—an excellent model for PBMC reconstitution and pharmacodynamic evaluation in the absence of GvHD. J Immunol. 2023;89 (1_Supplement ): (210):22‐23.
104 Yaguchi T , Kobayashi A , Inozume T , et al. Human PBMC‐transferred murine MHC class I/II‐deficient NOG mice enable long‐term evaluation of human immune responses. Cell Mol Immunol. 2018;15 (11 ):953‐962.29151581
105 Takahashi T , Katano I , Ito R , et al. Enhanced antibody responses in a novel NOG transgenic mouse with restored lymph node organogenesis. Front Immunol. 2017;8 :2017.29387068
106 Li Y , Masse‐Ranson G , Garcia Z , et al. A human immune system mouse model with robust lymph node development. Nat Methods. 2018;15 (8 ):623‐630.30065364
107 Mendelson A , Frenette PS . Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20 (8 ):833‐846.25100529
108 Majumdar MK , Thiede MA , Haynesworth SE , Bruder SP , Gerson SL . Human marrow‐derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long‐term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res. 2000;9 (6 ):841‐848.11177595
109 Ran Y , Dong Y , Li Y , et al. Mesenchymal stem cell aggregation mediated by integrin alpha4/VCAM‐1 after intrathecal transplantation in MCAO rats. Stem Cell Res Ther. 2022;13 (1 ):507.36273220
110 Zhang Y , Chai C , Jiang XS , Teoh SH , Leong KW . Co‐culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. Tissue Eng. 2006;12 (8 ):2161‐2170.16968157
111 Carrancio S , Romo C , Ramos T , et al. Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant. 2013;22 (7 ):1171‐1183.23031585
112 Garrigos MM , de Oliveira FA , Nucci MP , et al. How mesenchymal stem cell cotransplantation with hematopoietic stem cells can improve engraftment in animal models. World J Stem Cells. 2022;14 (8 ):658‐679.36157912
113 Yin X , Hu L , Zhang Y , et al. PDGFB‐expressing mesenchymal stem cells improve human hematopoietic stem cell engraftment in immunodeficient mice. Bone Marrow Transplant. 2020;55 (6 ):1029‐1040.31804621
114 Hansen M , Stahl L , Heider A , et al. Reduction of graft‐versus‐host‐disease in NOD.Cg‐Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NSG) mice by Cotransplantation of syngeneic human umbilical cord‐derived mesenchymal stromal cells. Transplant Cell Ther. 2021;27 (8 ):651‐658.
115 Le Blanc K , Rasmusson I , Sundberg B , et al. Treatment of severe acute graft‐versus‐host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363 (9419 ):1439‐1441.15121408
116 Hu L , Cheng H , Gao Y , et al. Antioxidant N‐acetyl‐L‐cysteine increases engraftment of human hematopoietic stem cells in immune‐deficient mice. Blood. 2014;124 (20 ):e45‐e48.25287706
117 Zeleniak A , Wiegand C , Liu W , et al. De novo construction of T cell compartment in humanized mice engrafted with iPSC‐derived thymus organoids. Nat Methods. 2022;19 (10 ):1306‐1319.36064772
118 Ramos SA , Armitage LH , Morton JJ , et al. Generation of functional thymic organoids from human pluripotent stem cells. Stem Cell Reports. 2023;18 (4 ):829‐840.36963390
119 Provin N , Giraud M . Differentiation of pluripotent stem cells into thymic epithelial cells and generation of thymic organoids: applications for therapeutic strategies against APECED. Front Immunol. 2022;13 :930963.35844523
120 Reinisch A , Thomas D , Corces MR , et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22 (7 ):812‐821.27213817
